公开(公告)号：WO2023082220A1

公开(公告)日：2023-05-19

申请号：PCT/CN2021/130493

申请日：2021-11-13

申请人： 广东暨创硒源纳米研究院有限公司

发明人： 李晓玲 ,  陈填烽 ,  刘婷 ,  陈义康 ,  李海伟

IPC分类号： A61K47/51 ,  A61K47/58 ,  A61K47/61 ,  A61K47/66 ,  A61K33/04 ,  A61K31/155 ,  A61K35/00

摘要： 功能化纳米硒联合二甲双胍制备NK细胞增敏剂，所述功能化纳米硒为单独纳米硒，聚丙烯胺盐酸盐修饰的纳米硒，聚乙烯吡咯烷酮修饰的纳米硒，吐温80修饰的纳米硒，多糖修饰的纳米硒，叶酸修饰的肿瘤靶向性纳米硒和转铁蛋白修饰的肿瘤靶向性纳米硒中的至少一种；所属NK细胞为NK92细胞。所述NK细胞增敏剂能够辅助NK细胞进行应用，刺激NK细胞分泌更多的细胞因子从而提高细胞治疗的抗肿瘤效果。

公开(公告)号：WO2022201063A1

公开(公告)日：2022-09-29

申请号：PCT/IB2022/052660

申请日：2022-03-23

申请人： COVABIND JOINT RESEARCH PRIVATE LIMITED

发明人： MADHAIYAN, Kalaipriya ,  SRIRAM, Harini

IPC分类号： A61K47/66

摘要： The invention provides a nanoparticle proteolysis targeting chimeras used for selectively inducing degradation of a targeted protein. More particularly invention provides nanoparticle composition comprising compound of Formula (I), their use as medicinal agent and process of their preparation.

公开(公告)号：WO2022178634A1

公开(公告)日：2022-09-01

申请号：PCT/CA2022/050263

申请日：2022-02-24

申请人： TRANSFERT PLUS, SOCIÉTÉ EN COMMANDITE ,  THERATECHNOLOGIES INC.

发明人： BÉLIVEAU, Richard ,  DEMEULE, Michel ,  ANNABI, Borhane ,  CHARFI, Cyndia ,  LAROCQUE, Alain ,  CURRIE, Jean-christophe ,  ZGHEIB, Alain ,  MARSOLAIS, Christian

IPC分类号： A61K47/66 ,  A61K51/08 ,  A61P35/00 ,  C07K7/08 ,  C07K14/00

摘要： The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

公开(公告)号：WO2022165043A2

公开(公告)日：2022-08-04

申请号：PCT/US2022/014107

申请日：2022-01-27

申请人： CSTS HEALTH CARE INC.

发明人： KLEMENT, Giannoula Lakka ,  LIU, Qian

IPC分类号： C12N5/078 ,  A61K35/19 ,  A61K47/64 ,  A61K47/66 ,  C07K17/02 ,  C07K14/47

摘要： The present disclosure provides compositions and methods comprising platelets loaded with at least two agents, with each agent being loaded into a distinct ?-granule type of the platelet. Agents loaded into platelets are generally protected from degradation and the subject is protected from toxicity, if any, from the agent. These benefits, coupled with the platelets' natural ability to home to sites of injury, inflammation, and/or angiogenesis, helps ensure that a therapeutically effective amounts of the agents are delivered to a target site.

公开(公告)号：WO2022150869A1

公开(公告)日：2022-07-21

申请号：PCT/AU2021/050023

申请日：2021-01-13

申请人： UNIVERSITY OF NEWCASTLE

发明人： AITKEN, Robert John ,  SMITH, Lee Brett

IPC分类号： A61K38/17 ,  A61K38/16 ,  A61K47/42 ,  A61K47/66 ,  A61P15/16 ,  A61P15/18 ,  A61K9/51

摘要： Nanoparticle constructs and compositions and methods thereof containing one or more peptides that each bind to a receptor of a reproductive cell (including a follicle stimulating hormone receptor or a luteinizing hormone receptor), and an apoptotic or cytotoxic protein or a polynucleotide encoding the apoptotic or cytotoxic protein, such as Diphtheria toxin A ("DTA") are described herein. The nanoparticles comprise surface peptides that can bind to reproductive cell receptors and cause cell death. The methods comprise administering the nanoparticle constructs or compositions thereof for the sterilization of subjects, including male and female cats and dogs.

公开(公告)号：WO2022125562A1

公开(公告)日：2022-06-16

申请号：PCT/US2021/062233

申请日：2021-12-07

申请人： JANUX THERAPEUTICS, INC. [US]/[US]

发明人： CAMPBELL, David ,  DIRAIMONDO, Thomas R.

IPC分类号： A61K38/08 ,  A61K47/66 ,  C07K7/06 ,  C12N15/62 ,  A61K38/00

摘要： Disclosed herein are polypeptide and polypeptide complex compositions that comprise a peptide that selectively impairs binding of an anti-CD3 binding domain to CD3 in healthy tissue but not in a disease state.

公开(公告)号：WO2022077102A1

公开(公告)日：2022-04-21

申请号：PCT/CA2021/051433

申请日：2021-10-12

申请人： MEDICENNA THERAPEUTICS, INC.

发明人： MERCHANT, Fahar

IPC分类号： A61K47/66 ,  A61K39/395 ,  A61K49/00 ,  A61P25/00 ,  A61P35/00 ,  C07K16/22 ,  C07K19/00 ,  G01N33/48 ,  G01N33/574

摘要： Methods for treating a central nervous system (CNS) tumor in a subject, comprising administering to the subject MDNA55 in combination with a vascular endothelial growth factor A (VEGF-A) inhibitor administered at a subtherapeutic level.

公开(公告)号：WO2021142217A1

公开(公告)日：2021-07-15

申请号：PCT/US2021/012637

申请日：2021-01-08

申请人： DYNE THEREAPEUTICS, INC.

发明人： SUBRAMANIAN, Romesh R. ,  QATANANI, Mohammed T. ,  WEEDEN, Timothy ,  DESJARDINS, Cody A. ,  QUINN, Brendan

IPC分类号： A61K31/7088 ,  A61K31/7105 ,  A61K39/395 ,  A61K47/66 ,  A61K47/68 ,  C07K16/28

摘要： Aspects of the disclosure relate to molecular payloads that modulate the expression or activity of MLCK1 and complexes comprising a muscle-targeting agent covalently linked to the molecular payloads. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell (e.g., a smooth muscle cell). In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

公开(公告)号：WO2021108929A1

公开(公告)日：2021-06-10

申请号：PCT/CA2020/051686

申请日：2020-12-07

申请人： THERATECHNOLOGIES INC.

发明人： MARSOLAIS, Christian ,  DEMEULE, Michel ,  CURRIE, Jean-Christophe ,  LAROCQUE, Alain

IPC分类号： A61K47/62 ,  A61K47/66 ,  A61P35/00 ,  C07K14/00 ,  C07K14/195 ,  C07K14/47 ,  C07K14/705 ,  C07K7/08

摘要： The present disclosure relates to compositions comprising a solubilizing agent and a peptide compound and/or a conjugate compound, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the conjugate compounds can comprise the formula of A-(B)n, wherein A is a peptide compound; and B is at least one therapeutic agent, and the peptide compounds can comprise compounds of formula X1X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY (II) (SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L (III) (SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

公开(公告)号：WO2021068879A1

公开(公告)日：2021-04-15

申请号：PCT/CN2020/119919

申请日：2020-10-09

申请人： 复旦大学

发明人： 陆伟跃 ,  郭海燕 ,  谢操

IPC分类号： A61K47/64 ,  A61K47/66 ,  A61K39/395 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00

摘要： 本发明属于药学技术领域，涉及一种靶向功能分子修饰的抗体复合物，本发明将靶向功能分子与抗体通过一定的方式连接形成复合物，用于改善抗体在治疗脑部疾病时，如脑肿瘤(血-脑屏障和血-脑肿瘤屏障)、阿尔兹海默症和帕金森病(血-脑屏障)由于无法跨越相关生物屏障而影响其疗效的问题，试验结果显示：本发明的靶向功能分子修饰的抗体复合物不影响抗体的活性，能克服生物屏障的限制，促使抗体跨生物屏障进入病灶部位，并在病灶部位微环境响应下释放抗体，显著改善抗体对脑部疾病的治疗效果，具有良好的临床应用前景。